Company news

Biomea Fusion, Inc. news in 2022

Biomea Fusion, Inc.'s news releases, calls and decks from 2022, newest first.

View company

Biomea Fusion Announces FDA Clearance of Investigational New Drug (IND) Application for Covalent Menin Inhibitor BMF-219 in Type 2 Diabetes

December 13, 2022

Biomea Fusion Reports Third Quarter 2022 Financial Results and Business Highlights

November 6, 2022

Biomea Fusion to Present Preclinical Data for BMF-500, an Investigational Oral Covalent FLT3 Inhibitor, at the 64th American Society of Hematology (ASH) Annual Meeting

November 2, 2022

Biomea Fusion Announces Dosing of First Patient with Type 2 Diabetes and Completion of Phase I Healthy Volunteer Portion of Phase I/II (COVALENT-111) Study of BMF-219

October 30, 2022

Biomea Fusion Announces First Patient Dosed with Chronic Lymphocytic Leukemia (CLL) in COVALENT-101 Trial

October 26, 2022

BMF-219 Enters the Clinic for KRAS Solid Tumors

October 13, 2022

Biomea Fusion Presents New Preclinical Data at the European Association for the Study of Diabetes (EASD) Annual Meeting Describing BMF-219’s Potential as a Novel, Oral, Long-Acting Treatment for Type 2 Diabetes

September 19, 2022

Biomea Fusion Presents Additional Preclinical Data Demonstrating Anti-Tumor Activity and Mechanistic Evidence for BMF-219 in Diffuse Large B-Cell Lymphoma and Multiple Myeloma Models at International Myeloma Society Annual Meeting

August 25, 2022

Biomea Fusion Reports Second Quarter 2022 Financial Results and Business Highlights

July 31, 2022

Biomea Fusion Selected for Two Oral Presentations at the European Association for the Study of Diabetes Annual Meeting Describing BMF-219’s Potential as a Novel, Oral, Long-Acting, Acute Treatment for Type 2 Diabetes

June 30, 2022

Biomea Fusion Announces First Patient Dosed in Multiple Myeloma Cohort of COVALENT-101 Trial

June 21, 2022

Biomea Fusion to Present New Preclinical Data Showing BMF-219’s Strong Activity in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Tumor Models at ASCO 2022

May 25, 2022

Biomea Fusion Announces IND Candidate Selection: BMF-500, a Potential Best-in-Class Oral Covalent Inhibitor of FLT3

May 18, 2022

Biomea Fusion Reports First Quarter 2022 Financial Results and Business Highlights

May 15, 2022

Biomea Fusion Announces Acceptance of Multiple Abstracts at the 2022 ASCO Annual Meeting

April 26, 2022

Biomea Fusion Reports Preclinical Data on BMF-219 and Trial in Progress Presentations at AACR 2022 Annual Meeting

April 7, 2022

Biomea Fusion Announces Acceptance of Late Breaking Presentation of Lead Menin Inhibitor BMF-219 in Diabetes at ADA 82nd Scientific Sessions 2022

April 5, 2022

Biomea Fusion Announces Presentation of Lead Menin Inhibitor BMF-219 in Diabetes at ADA 82nd Scientific Sessions 2022

March 13, 2022

Biomea Fusion Announces Upcoming Presentations of Preclinical Data in Diffuse Large B-Cell Lymphoma, Multiple Myeloma, and Several KRAS Mutant Solid Tumors for BMF-219 at AACR Annual Meeting 2022

March 7, 2022

Biomea Fusion Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Highlights

February 27, 2022

Biomea Fusion Announces Appointment of Steve Morris, M.D. as Chief Medical Officer

January 31, 2022

Biomea Fusion Announces First Patient Dosed

January 24, 2022

Biomea Fusion Announces 2022 Clinical Development Plan to Initiate Studies in up to Seven Different Tumor Types and in Diabetes for BMF-219

January 9, 2022

Biomea Fusion Releases Pre-Clinical Data with BMF-219 in Diabetes

January 5, 2022

Biomea Fusion Moves into New Headquarters and Expands R&D Facility

January 3, 2022

Decks in 2022